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Background: We investigated levels of the β-amyloid 1–42 (Aβ42), total tau protein (T-tau) and tau phosphorylated
at position threonine 181 (P-tau) in cerebrospinal fluid (CSF) of idiopathic normal pressure hydrocephalus (iNPH)
patients and tried to find their clinical implications in the evaluation and treatment of iNPH.
Method: Twenty-five possible iNPH patients were prospectively enrolled and their CSF was collected to analyze
levels of Aβ42, T-tau and P-tau using ELISA method. Gait disturbance, urinary incontinence, and cognitive
impairment were semi-quantified and detailed neuropsychological (NP) test was performed.
Result: Eight iNPH patients were classified into the lower CSF Aβ42 group and 17 patients were classified into the
higher CSF Aβ42 group. There was no difference in the iNPH grading score and its improvement after LP between
the two groups. The lower CSF Aβ42 group showed more deficits in attention, visuospatial function and verbal
memory in the baseline NP test and less improvement in phonemic categorical naming and frontal inhibitory
function after LP.
Conclusions: Our study suggested that concomitant AD in iNPH patients might contribute to lumbar puncture or
shunt unresponsiveness, especially in the field of cognitive dysfunction.
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Neuropsychological testsBackground
Idiopathic normal pressure hydrocephalus (iNPH) is char-
acterized by a clinical triad of symptoms including cogni-
tive impairment, gait difficulty, and urinary incontinence
along with ventricular enlargement in brain imaging [1,2].
It is a potentially reversible cause of cognitive and motor
impairment in older adults using ventriculo-peritoneal
(VP) shunt or ventriculo-atrial (VA) shunt operation.
While treatment with VP shunts is widely used and effect-
ive, the complication rate is high [3] and the risk factors
for shunt unresponsiveness are poorly understood. A
possible contributor to shunt unresponsiveness is the* Correspondence: symoon.bv@gmail.com
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unless otherwise stated.presence of comorbid neurologic conditions that are com-
mon in the aged, such as Alzheimer’s disease (AD) [4].
AD and iNPH have different pathomechanism, but
recent studies pointed out common pathomechanism
between the two diseases [5,6]. However there is still
controversy about the clinical implications of the coexist-
ence of AD pathology in iNPH patients. Some suggested
that AD was only a bystander and the rate of coexistence
of AD was similar to that of normal population [7-9] while
the others reported the poor shunt response was possibly
due to AD pathology [4,10]. Since the introduction of
ELISA method to detect cerebrospinal fluid (CSF) bio-
markers for AD, there have been many studies about the
differential role of levels of the β-amyloid 1–42 (Aβ42),
T-tau protein (T-tau) and tau phosphorylated at position
threonine 181 (P-tau) in CSF of iNPH patients [11-15].
However, there are still debates about the level of each. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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changes [16,17].
The aim of this study was to investigate levels of the
Aβ42, T-tau and P-tau in CSF of iNPH patients and




Among patients who visited the Department of Neurology
at the Ajou Medical Center, Suwon, Korea from March
2010 to February 2012, we consecutively recruited 25 pa-
tients who satisfied the criteria for possible iNPH. All pa-
tients had had brain MRIs and an LP. The clinical criteria
for possible iNPH included following: (1) MRI showing
ventricular enlargement (2) Any one symptom from clin-
ical triad (gait disturbance, cognitive deficit or urinary dis-
turbance) which was considered as a symptom compatible
with iNPH by the clinician [2]. After making a diagnosis
of iNPH, one or two LPs were performed to drain 30 to
50 ml of the CSF and 10 ml of CSF was collected to evalu-
ate biomarkers for AD. The diagnosis of iNPH was made
independently from the patients’ response to the LPs.
The CSF of 17 AD patients and 10 normal control sub-
jects which were collected and stored previously at two
other hospitals (S.C.H.U.H. and C.A.U.H.) was tested to
get a cutoff value of the coexistence of AD. All AD
patients met the criteria for probable AD as proposed by
the National Institute of Neurological and Communicative
Diseases and Stroke and Alzheimer’s disease and Related
Disorders Association (NINCDS-ADRDA) [18]. All nor-
mal control subjects scored in each cognitive domain test
higher than the cutoff value. The cutoff values for each
test score were represented as a –1.0 SD below the pub-
lished norms for their age and education group [19].
We excluded patients with a history of significant hearing
or visual impairment that could render interview participa-
tion difficult, as well as those with a history of other
neurological disorders (e.g., idiopathic Parkinson’s disease,
dementia with Lewy bodies, or active epilepsy), psychiatric
illnesses (e.g., schizophrenia, mental retardation, major de-
pression, or mania), those taking psychotropic medications,
and those with a history of significant alcohol and/or other
substance abuse. Each patient provided written informed
consent. If patients had impaired decisional capacity, care-
givers provided consent and patients provided assent. This
study was approved by the Ajou Institutional Review Board.
Evaluation of iNPH symptoms
An iNPH scale modified from Larsson et al. [20] and
Krauss et al. [21] that assessed gait [1 = normal, 2 = walk
without any assistive device but insecure, 3 = walk with
cane, 4 = walk with bimanual support (walker), 5 = walk
aided by an assistant, 6 = wheelchair-bounded], urinarydisturbance (0 = normal, 1 = sporadic (1–3 or more times
per week but less than once per day) incontinence or urge
phenomena, 2 = frequent (1 or more times per day) incon-
tinence or urge phenomena, and 3 = no or minimal con-
trol of bladder function) and cognitive deficit (0 = normal,
1 =minimal attention or memory deficits, 2 = considerable
attention or memory deficits but oriented to situational
context, and 3 = not or only marginally oriented to situ-
ational context) was used to characterize and grade the
clinical syndrome. Patients were evaluated both before
and 4 to 6 hours after the LP.
Sample collection
All participants underwent LP in the L3-4 or L4-5 inter-
space to drain 30 ~ 50 ml of CSF to evaluate response to
LP from 10:00 to 12:00. During the procedure, 10 ml of
CSF was collected in polypropylene tubes after discard-
ing the first 3 ~ 4 ml. Bloody or cloudy samples were
rejected. No serious adverse events were reported. The
samples were immediately centrifuged for 15 minutes at
2,000 rpm to remove cells and aliquots were stored in
polypropylene tubes and immediately frozen at −80°C
until analysis. They were thawed just before analysis.
ELISA methods
CSF T-tau concentration was determined using a sandwich
enzyme-linked immunosorbent assay ([ELISA] Innotest
hTAU-Ag, Innogenetics, Ghent, Belgium) specifically
constructed to measure all tau isoforms irrespective of
phosphorylation status, as previously described [22].
P-tau was measured using a sandwich ELISA method
(Innotest Phospho-Tau[181P]), as previously described
[23]. Aβ42 levels were determined using a sandwich
ELISA (Innotest β-amyloid [1-42]), specifically constructed
to measure amyloid-β containing both the 1st and 42nd
amino acids, as previously described [24]. All biomarker
levels were measured in duplicate according to the manu-
facturer’s instructions. The CSF samples of iNPH patients
were analyzed twice using different aliquot.
Magnetic resonance image
The Evans index and white matter hyperintensity were
assessed using MRI. The Evans index was defined as the
maximal frontal horn ventricular width divided by the
transverse inner diameter of the skull and signifies
ventriculomegaly if it is 0.3 or greater [2]. White matter
hyperintensity was evaluated by the method designed by
Clinical Research for Dementia of South Korea Study
(CREDOS). Both periventricular (1-3) and deep (1-3)
white matter hyperintensities were assessed [25]. Each
longest-diameter white matter change around the lateral
ventricles (capping or banding on the periventricular
areas) or deep in white matter (especially the centrum
semiovale) were evaluated separately. The deep white
Table 1 Demographic and clinical characteristics of the subject groups (N = 52)
iNPH AD Control p1 p2 p3
n (M/F) 25 (12/13) 17 (10/7) 10 (3/7)
Age, yr 73.3 ± 7.0 72.2 ± 10.0 63.0 ± 6.7 0.924 0.029* 0.090
Education, yr 8.5 ± 5.2 6.1 ± 5.6 5.5 ± 5.2 0.469 0.498 0.970
K-MMSE 19.5 ± 6.9 18.3 ± 2.1 26.6 ± 2.5 0.832 0.042* 0.029*
Aβ42, pg/ml 579.8 ± 182.3 409.2 ± 166.1 691.8 ± 212.7 0.013* 0.241 0.001*
T-tau, pg/ml 131.9 ± 77.6 259.6 ± 161.5 196.9 ± 114.4 0.003* 0.312 0.382
P-tau, pg/ml 27.0 ± 9.6 51.3 ± 28.3 43.0 ± 28.5 0.002* 0.123 0.597
Continuous variables are presented as mean ± standard deviation. iNPH: Idiopathic Normal Pressure Hydrocephalus; AD: Alzheimer’s Disease; M: Male; F: Female;
K-MMSE: Korean version of Mini Mental Status Exam; p1: p-value between iNPH and AD; p2: p-value between iNPH and control; p3: p-value between AD and control.
*p < 0.05.
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< 25 mm), or 3 (≥ 25 mm) and periventricular white matter
changes were rated as 1 (< 5 mm) or 2 (≥ 5 mm, < 10 mm),
or 3 (≥ 10 mm). Hippocampal atrophy was graded by
Scheltens’ method [26].Figure 1 Levels of CSF Aβ42 (A), T-tau (B) and P-tau (C) in the subjectNeuropsychological tests
Neuropsychologists assessed participants’ cognitive func-
tioning via the extensive Seoul Neuropsychological
Screening Battery (SNSB) [19] covering five specific cog-
nitive domains, as follows.groups.
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used the digit span forward and backward tests.
(2) The language function assessment employed the
Korean version of the Boston Naming Test
(K-BNT) [27].
(3) The visuospatial function assessment was the
patient’s copy score of the Rey Complex Figure
Test (RCFT), neuropsychological assessment in
which examinees are asked to reproduce a
complicated line drawing, first by copying and then
from memory.
(4) Memory function was divided into verbal and
visual memory. We assessed verbal memory by
means of the Seoul Verbal Learning Test (SVLT),
the Korean version of the revised Hopkins Verbal
Learning Test (HVLT-R), testing participants on
the immediate recall, delayed recall, and
recognition tasks. To assess visual memory, we
tested participants on the RCFT’s immediate recall,
delayed recall, and recognition tasks.
(5) To assess frontal lobe functioning, we used the
contrasting program, go-no go, the semantic and
phonemic aspects of the Controlled Oral Word
Association Test (COWAT) and Stroop test.Statistical analysis
We used chi-square, analysis of variance (ANOVA), and
Kruskal-Wallis tests to compare demographic data of
each group and analysis of covariance (ANCOVA) to
compare clinical data and the neuropsychological test
percentile scores adjusted by the age, gender and yearsFigure 2 Receiver operating characteristic (ROC) curve of CSF Aβ42 foof education of normative data from general population.
Post-hoc analyses with Least Significant Difference (LSD)
method were performed for between-group comparisons.
Intraclass correlation coefficient was calculated to show
the test-retest reliability of ELISA. Receiver operating
characteristics (ROC) curve analysis was used to identify
the cut-off levels with the optimal combination of specifi-
city and sensitivity. Mann-Whitney test was used to com-
pare the scores of neuropsychological tests between the
subgroups of iNPH patients, adjusted for age, sex and dur-
ation of education. All statistical analyses were performed
using SPSS 13.0 (SPSS Inc, Chicago, IL, USA). Null hy-
potheses of no difference were rejected if p-values were
less than .05.Results
Demographic and clinical characteristics of the subject
groups
Demographic and clinical characteristics and results
of statistical analyses are summarized in Table 1 and
plotted in Figure 1. The age of AD group was signifi-
cantly older than the control group (p = 0.029). The
intraclass correlation coefficient of Aβ42, T-tau and
P-tau were 0.922, 0.908 and 0.960, respectively. The
mean value of the two test results of each analysis
was used for statistical analyses. CSF Aβ42 level of
AD was significantly lower than iNPH (p = 0.013) and
control group (p = 0.001) after adjustment for age, sex
and duration of education. CSF T-tau and P-tau levels
were significantly higher in AD than iNPH (p = 0.003
and p = 0.002, respectively).r discrimination between the control and AD patient groups.
Table 2 Demographic and clinical data of the iNPH






n (M/F) 8 (3/5) 17 (9/8) 0.673
Age, yr 76.1 ± 7.3 72.0 ± 6.7 0.187
Education, yr 7.7 ± 5.6 8.7 ± 5.2 0.687
K-MMSE 16.8 ± 6.6 20.8 ± 6.9 0.193
Disease duration, day 724.1 ± 513.6 769.4 ± 520.4 0.857
Aβ42, pg/ml 368.7 ± 72.3 679.1 ± 121.7 <0.001*
T-tau, pg/ml 145.7 ± 103.9 125.3 ± 64.6 0.551
P-tau, pg/ml 28.2 ± 13.8 26.4 ± 7.3 0.682
Evans ratio 0.34 ± 0.02 0.36 ± 0.03 0.277
DWMH 1.6 ± 0.9 1.5 ± 0.8 0.804
PVWMH 2.0 ± 0.7 1.9 ± 0.7 0.856
Hippocampal atrophy 1.6 ± 0.9 0.7 ± 0.6 0.020*
Pre-gait score 2.75 ± 1.48 2.59 ± 1.54 0.807
Pre-urinary score 1.00 ± 1.06 0.94 ± 0.96 0.892
Pre-cognition score 1.50 ± 0.75 1.41 ± 0.79 0.795
Pre-iNPH score sum 4.13 ± 2.94 3.94 ± 2.86 0.883
Post-gait score 2.00 ± 1.69 2.00 ± 1.11 1.000
Post-urinary score 0.63 ± 1.06 0.47 ± 0.80 0.689
Post-cognition score 1.38 ± 0.91 1.12 ± 0.78 0.474
Post-iNPH score sum 3.00 ± 3.38 2.65 ± 2.14 0.753
Gait score improvement 0.75 ± 0.70 0.59 ± 0.87 0.651
Urinary score
improvement
0.38 ± 0.74 0.47 ± 0.71 0.761
Cognition score
improvement
0.13 ± 0.35 0.29 ± 0.47 0.377
iNPH score improvement 1.25 ± 1.48 1.29 ± 0.68 0.950
Continuous variables are presented as mean ± standard deviation. iNPH:
Idiopathic Normal Pressure Hydrocephalus; AD: Alzheimer’s Disease; M: Male;
F: Female; K-MMSE: Korean version of Mini Mental Status Exam; PVWMH:
Periventricular White Matter Hyperintensity; DWMH: Deep White
Matter Hyperintensity. *p < 0.05.
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results
To determine a cut-off level of the coexistence of AD in
iNPH patients, ROC curve analysis was performed. CSF
Aβ42 was used because it was the only biomarker which
was significantly different between AD and control group.
The area under the curve was 0.876 with p-value of 0.001
(Figure 2). Following recommendations of previous stud-
ies, sensitivity more than 85% was selected in the deter-
mination of cutoff level of 490 pg/ml, similar to the
previous study (482 pg/ml) [28].
Demographic and clinical characteristics of the iNPH
patient subgroups
Eight iNPH patients were classified into the lower CSF
Aβ42 group and 17 patients were classified into the
higher CSF Aβ42 group. We statistically compared the
lower CSF Aβ42 group and the higher CSF Aβ42 group
using the Mann-Whitney test. There was no difference
in age, sex and duration of education. Among the vari-
ables tested, hippocampal atrophy grade was significantly
higher in the lower CSF Aβ42 group than the higher
CSF Aβ42 group (p = 0.02). There was no difference in
the iNPH grading score and improvement rate after LP
between the two groups (Table 2).
Neuropsychological test results of the iNPH patient
subgroups according to CSF Aβ42 level
A total of 18 iNPH patients underwent detailed neuro-
psychological tests as an initial evaluation before CSF
drainage. Seven patients belonged to the lower CSF Aβ42
group and 11 belonged to the higher CSF Aβ42 group.
Among the neuropsychological test scores, the lower CSF
Aβ42 group had a lower score in Digit span forward test
(p = 0.018), RCFT copy test (p = 0.043) and SVLT immedi-
ate recall test (p = 0.009) after adjustment for age, sex and
duration of education (Table 3, A).
In a subset analysis of 10 patients who underwent
follow-up neuropsychological tests after CSF drainage,
the lower CSF Aβ42 group showed significantly less im-
provement in phonemic COWAT (p = 0.008) and color
reading test in Stroop test (p = 0.018) after LP compared
to the higher CSF Aβ42 group after adjustment for age,
sex and duration of education. The mean interval be-
tween the first and the second neuropsychological test
was 13.2 ± 9.4 days (Table 3, B).
Discussion
Although there have been a few studies about the coex-
istence of AD in iNPH patients and its clinical implica-
tion, to the best of our knowledge, this is the first study
which reports the difference in detailed neuropsycho-
logical tests before and after CSF drainage according to
CSF biomarkers for AD. The major findings of this studywere as follows: (1) All three biomarkers for AD diagno-
sis were significantly different between AD and iNPH.
(2) There was no difference in demographic and clinical
characteristics including the response to CSF drainage
using iNPH grading system between the lower CSF
Aβ42 group and the higher CSF Aβ42 group. (3) Compari-
son of initial neuropsychological tests showed deficits in
attention, visuospatial function and verbal memory are
more prominent in the lower CSF Aβ42 group than the
higher CSF Aβ42 group. (4) Neuropsychological perform-
ance improvement before and after CSF drainage were
significantly less in phonemic categorical naming and
frontal inhibitory function in the lower CSF Aβ42 group
than the higher CSF Aβ42 group.
In the comparison of Aβ42, T-tau and P-tau between
iNPH and AD, Aβ42 was lower and T-tau and P-tau were
Table 3 Neuropsychological test results of the iNPH patient subgroups by CSF Aβ42 level before CSF drainage
(N = 18, A) and change before and after CSF drainage (N = 10, B)
(A) (B)
Lower CSF Aβ42 Higher CSF Aβ42 P Lower CSF Aβ42 Higher CSF Aβ42 p
(n = 7) (n = 11) (n = 5) (n = 5)
Attention
Digit span forward test 4.7 ± 1.1 6.2 ± 1.4 0.018* 0.2 ± 1.3 -0.6 ± 0.8 0.131
Digit span backward test 2.0 ± 1.5 2.7 ± 1.1 0.271 0.0 ± 0.7 -0.2 ± 0.8 0.911
Language function
K-BNT 25.3 ± 6.6 36.1 ± 14.3 0.157 2.4 ± 6.5 0.6 ± 3.6 0.602
Visuospatial function
RCFT Copy 12.8 ± 10.7 23.7 ± 12.5 0.043* 0.1 ± 4.5 -1.0 ± 2.1 0.577
Memory function
SVLT immediate recall 6.8 ± 1.9 13.3 ± 3.6 0.009* 2.0 ± 3.0 4.2 ± 3.8 0.117
SVLT delayed recall 0.1 ± 0.3 1.8 ± 2.0 0.204 0.0 ± 0.0 2.0 ± 1.8 0.054
SVLT recognition 15.5 ± 2.9 15.9 ± 4.0 0.820 -1.0 ± 4.1 1.4 ± 2.8 0.602
RCFT immediate recall 2.9 ± 4.3 7.9 ± 6.7 0.129 -0.8 ± 2.5 2.2 ± 3.5 0.245
RCFT delayed recall 1.8 ± 2.8 6.6 ± 6.2 0.232 0.3 ± 2.3 3.0 ± 3.2 0.245
RCFT recognition 16.0 ± 3.3 16.9 ± 3.1 0.480 -2.6 ± 3.2 2.0 ± 3.0 0.465
Frontal function
Contrasting program 15.0 ± 8.3 14.2 ± 9.1 0.691 -0.2 ± 0.4 0.2 ± 0.4 0.180
Go-no go 9.6 ± 10.2 11.0 ± 9.1 0.499 3.2 ± 8.9 2.8 ± 6.2 0.451
Semantic COWAT 6.3 ± 3.9 8.8 ± 6.1 0.269 -1.4 ± 3.3 5.4 ± 6.1 0.117
Phonemic COWAT 10.0 ± 6.0 14.4 ± 11.4 0.926 -1.0 ± 1.7 5.4 ± 6.1 0.018*
Stroop test: color reading 26.0 ± 13.2 44.5 ± 35.9 0.905 -4.4 ± 9.5 8.2 ± 8.1 0.008*
Continuous variables are presented as mean ± standard deviation. iNPH: Idiopathic Normal Pressure Hydrocephalus; AD: Alzheimer’s Disease; K-BNT: Korean version
of Boston Naming Test; RCFT: Rey Complex Figure Test; SVLT: Seoul Verbal Learning Test; COWAT: Controlled Oral Word Association Test.
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with earlier studies which reported various CSF bio-
markers indicating less AD pathology in iNPH patients
than AD patients [11,29,30]. After determination of cutoff
level of AD using ROC analysis of CSF biomarkers in AD
and control group, 8 out of 25 iNPH patients (32%) were
classified as having concomitant AD. This is consistent
with the overall prevalence of AD in normal elderly popu-
lation [31].In contrast to the consistent low Aβ42 level in
iNPH, there have been inconsistent reports regarding the
T-tau and P-tau levels. Some recent studies using ven-
tricular CSF during shunt procedure or external lumbar
drainage (ELD) reported higher T-tau and P-tau level in
iNPH patients [10,14,15].On the other hand, a recent re-
port investigating various biomarkers in lumbar and ven-
tricular CSF showed lower T-tau and P-tau level in iNPH
than normal control group [16]. Elevated T-tau level has
been detected in various diseases causing neuronal injury
such as stroke, trauma, hemorrhage and encephalitis
[32-34]. Shunt operation and ELD procedure might result
in neuronal injury and elevated T-tau and P-tau level in
these studies. Cortical neuronal injury from the advancedstage of iNPH and concomitant AD might affect this dis-
crepancy, as well.
Except for the hippocampal atrophy, all the radio-
logical and clinical symptomatic indicators of iNPH pa-
tients including response to CSF drainage did not differ
between the two subgroups divided by CSF Aβ42 level.
These results are similar to those of previous studies
which reported that iNPH patients benefit equally from
shunting regardless of the presence of AD pathology
[7-9]. Recently a study performed to compare CSF bio-
markers and response to ELD showed that none of the
biomarker predicted the ELD results [14]. However there
have been a few reports that cortical AD pathology and
ventricular CSF biomarker for AD resulted in a less robust
response to shunting [4,10]. Further long-term follow-up
study using simultaneous investigation of AD biomarkers
of cortical pathology and ventricular and lumbar CSF
might provide some of these answers.
Although there was no difference in general cognitive
function between the two subgroups, the initial detailed
neuropsychological tests revealed more deficits in atten-
tion, visuospatial function and verbal memory in the
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to be impaired in the early course of AD. Therefore
these results suggested that AD pathology may impact
an additive AD-related cognitive dysfunction in iNPH
patients regardless of underlying cognitive dysfunction
caused by iNPH. In addition to the initial difference,
categorical naming and inhibitory executive dysfunctions
in the lower CSF Aβ42 group, which were considered as
iNPH-related cognitive dysfunction, were less improved
after lumbar puncture compared to the higher CSF Aβ42
group. These results suggested that some portion of the
frontal lobe dysfunction in the lower CSF Aβ42 group was
possibly caused by the concomitant AD and not improved
after lumbar puncture. In contrast, the frontal lobe dys-
function in the higher CSF Aβ42 group was solely caused
by the pathophysiology of iNPH and improved more than
the lower CSF Aβ42 group. This pattern of improvement
after lumbar puncture was not reported before but the
similar pattern of post-shunt improvement was noted in a
previous study which observed improvement of subcor-
tical dysfunction after shunting [10].
We assumed that memory impairment and visuo-
spatial dysfunction in iNPH were mainly caused by con-
comitant AD which was defined by lower CSF Aβ42.
This assumption was usually correct in pure AD but the
correlation of the cognitive dysfunction with CSF bio-
markers is more complicated in iNPH. For example, in a
previous series of 17 iNPH cases, the visuospatial dys-
function was the prominent cognitive feature which was
against the classic view of iNPH as a subcortical, frontal
type of dementia [35]. Furthermore in a recent study,
the decreased CSF Aβ42 was not considered as a bio-
marker for concomitant AD but a consequence of a re-
duced brain metabolism secondary to the changed CSF
dynamic in iNPH [16]. However, there was neuropatho-
logical evidence that the CSF biomarkers for AD corre-
lated with cortical brain biopsy findings indicating AD
[17]. There were also studies showing that the memory
deficit as the leading symptom and cortical biopsy find-
ings predicted later development of AD in iNPH [36,37].
Further studies are warranted regarding the correlation
between the cognitive symptoms and CSF biomarkers
for AD in iNPH.
We should accept that this study has several limita-
tions. One limitation of this study is its relatively small
sample size. Another limitation is lack of analysis of
long-term follow-up data such as shunting history. The
authors also acknowledged that the possible iNPH cri-
teria is inclusive and the elevated T-tau and P-tau levels
might be induced by some different circumstances. In
addition, normal control subjects were recruited from
the clinic and possibly had cognitive complaint more
than those recruited from the cohort. Subjects with cog-
nitive complaint are known to have more AD pathologythan those without it [38]. This may affect the lack of
difference in T-tau and P-tau between AD and control
groups. The improvement after lumbar puncture may be
affected by the learning effect but there was a report that
no learning effect was found in patients with iNPH on
any of neuropsychological tests [39].
Conclusions
Our study suggested that concomitant AD in iNPH
patients might contribute to lumbar puncture or shunt
unresponsiveness, especially in the field of cognitive
dysfunction.
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